Homocysteine induces phosphatidylserine exposure in cardiomyocytes through inhibition of rho kinase and flippase activity

Cellular Physiology and Biochemistry

Volumn 28, Issue 1, 2011, Pages 53-62

  Sipkens, Jessica A ^a,b   Hahn, Nynke E ^a,b   Van Nieuw Amerongen, Geerten P ^a,b   Stehouwer, Coen D A ^a   Rauwerda, Jan A ^b   Van Hinsbergh, Victor W M ^a,b   Niessen, Hans W M ^a,b   Krijnen, Paul A J ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Flippase; Heart failure; Homocysteine; PS exposure; RhoA; ROCK

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; FLIPPASE; HOMOCYSTEINE; MEMBRANE PROTEIN; PHOSPHATIDYLSERINE; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HEART MUSCLE CELL; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

RATTUS;

EID: 80052017659     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000331713     Document Type: Article

References (34)

1. Symons JD, Mullick AE, Ensunsa JL, Ma AA, Rutledge JC: Hyperhomocysteinemia evoked by folate depletion: effects on coronary and carotid arterial function. Arterioscler Thromb Vasc Biol 2002;22:772-780. (Pubitemid 34517788)
2. Mudd SH, Finkelstein JD, Irreverre F, Laster L: Homocystinuria: An enzymatic effect. Science 1964;143:1443-1445.
3. Boers GH: Mild hyperhomocysteinemia is an independent risk factor of arterial vascular disease. Semin Thromb Hemost 2000;26:291-295.
4. Hoogeveen EK, Kostense PJ, Jakobs C, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD: Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes : 5-year follow-up of the Hoorn Study. Circulation 2000;101:1506-1511. (Pubitemid 30180885)
5. Sundstrom J, Vasan RS: Homocysteine and heart failure: a review of investigations from the Framingham Heart Study. Clin Chem Lab Med 2005;43:987-992. (Pubitemid 41581949)
6. Devi S, Kennedy RH, Joseph L, Shekhawat NS, Melchert RB, Joseph J: Effect of long-term hyperhomocysteinemia on myocardial structure and function in hypertensive rats. Cardiovasc Pathol 2006;15:75-82.
7. Joseph J, Joseph L, Shekhawat NS, Devi S, Wang J, Melchert RB, Hauer-Jensen M, Kennedy RH: Hyperhomocysteinemia leads to pathological ventricular hypertrophy in normotensive rats. Am J Physiol Heart Circ Physiol 2003;285:H679-H686. (Pubitemid 36885900)
8. Sipkens JA, Krijnen PA, Meischl C, Cillessen SA, Smulders YM, Smith DE, Giroth CP, Spreeuwenberg MD, Musters RJ, Muller A, Jakobs C, Roos D, Stehouwer CD, Rauwerda JA, van Hinsbergh V, Niessen HW: Homocysteine affects cardiomyocyte viability: concentration-dependent effects on reversible flip-flop, apoptosis and necrosis. Apoptosis 2007;12:1407-1418. (Pubitemid 46988284)
9. Bretscher MS: Asymmetrical lipid bilayer structure for biological membranes. Nat New Biol 1972;236:11-12.
10. Krijnen PA, Cillessen SA, Manoe R, Muller A, Visser CA, Meijer CJ, Musters RJ, Hack CE, Aarden LA, Niessen HW: Clusterin: a protective mediator for ischemic cardiomyocytes? Am J Physiol Heart Circ Physiol 2005;289:H2193-H2202. (Pubitemid 41507373)
11. Nijmeijer R, Lagrand WK, Baidoshvili A, Lubbers YT, Hermens WT, Meijer CJ, Visser CA, Hack CE, Niessen HW: Secretory type II phospholipase A(2) binds to ischemic myocardium during myocardial infarction in humans. Cardiovasc Res 2002;53:138-146. (Pubitemid 34020774)
12. Nijmeijer R, Willemsen M, Meijer CJ, Visser CA, Verheijen RH, Gottlieb RA, Hack CE, Niessen HW: Type II secretory phospholipase A2 binds to ischemic flipflopped cardiomyocytes and subsequently induces cell death. Am J Physiol Heart Circ Physiol 2003;285:H2218-H2224. (Pubitemid 37305968)
13. Krijnen PA, Sipkens JA, Molling JW, Rauwerda JA, Stehouwer CD, Muller A, Paulus WJ, van Nieuw Amerongen GP, Hack CE, Verhoeven AJ, van Hinsbergh V, Niessen HW: Inhibition of Rho-ROCK signaling induces apoptotic and nonapoptotic PS exposure in cardiomyocytes via inhibition of flippase. J Mol Cell Cardiol 2010;49:781-790.
14. Daleke DL: Regulation of transbilayer plasma membrane phospholipid asymmetry. J Lipid Res 2003;44:233-242. (Pubitemid 37303867)
15. de Korte D, Haverkort WA, van Gennip AH, Roos D: Nucleotide profiles of normal human blood cells determined by high-performance liquid chromatography. Anal Biochem 1985;147:197-209. (Pubitemid 15026063)
16. Kulkarni S, Goll DE, Fox JE: Calpain cleaves RhoA generating a dominantnegative form that inhibits integrininduced actin filament assembly and cell spreading. J Biol Chem 2002;277:24435-24441. (Pubitemid 34951967)
17. Sagara Y, Hirooka Y, Nozoe M, Ito K, Kimura Y, Sunagawa K: Pressor response induced by central angiotensin II is mediated by activation of Rho/Rhokinase pathway via AT1 receptors. J Hypertens 2007;25:399-406. (Pubitemid 46071938)
18. Bevers EM, Comfurius P, Dekkers DW, Zwaal RF: Lipid translocation across the plasma membrane of mammalian cells. Biochim Biophys Acta 1999;1439:317-330. (Pubitemid 29371798)
19. Grounds HR, Ng DC, Bogoyevitch MA: Small G-protein Rho is involved in the maintenance of cardiac myocyte morphology. J Cell Biochem 2005;95:529-542. (Pubitemid 41420183)
20. Lin G, Craig GP, Zhang L, Yuen VG, Allard M, McNeill JH, MacLeod KM: Acute inhibition of Rho-kinase improves cardiac contractile function in streptozotocindiabetic rats. Cardiovasc Res 2007;75:51-58. (Pubitemid 46873512)
21. Satoh S, Ueda Y, Koyanagi M, Kadokami T, Sugano M, Yoshikawa Y, Makino N: Chronic inhibition of Rho kinase blunts the process of left ventricular hypertrophy leading to cardiac contractile dysfunction in hypertensioninduced heart failure. J Mol Cell Cardiol 2003;35:59-70. (Pubitemid 36286968)
22. Shah DI, Singh M: Involvement of Rhokinase in experimental vascular endothelial dysfunction. Mol Cell Biochem 2006;283:191-199.
23. Wolfrum S, Dendorfer A, Rikitake Y, Stalker TJ, Gong Y, Scalia R, Dominiak P, Liao JK: Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol 2004;24:1842-1847. (Pubitemid 39350301)
24. Joseph J, Washington A, Joseph L, Koehler L, Fink LM, Hauer-Jensen M, Kennedy RH: Hyperhomocysteinemia leads to adverse cardiac remodeling in hypertensive rats. Am J Physiol Heart Circ Physiol 2002;283:H2567-H2574. (Pubitemid 35345964)
25. Maurer M, Burri S, de Marshi S, Hullin R, Martinelli M, Mohacsi P, Hess OM: Plasma homocysteine and cardiovascular risk in heart failure with and without cardiorenal syndrome. Int J Cardiol 2010;141:32-38.
26. Carroll JF, Tyagi SC: Extracellular matrix remodeling in the heart of the homocysteinemic obese rabbit. Am J Hypertens 2005;18:692-698. (Pubitemid 40692438)
27. Fadok VA, de Cathelineau A, Daleke DL, Henson PM, Bratton DL: Loss of phospholipid asymmetry and surface exposure of phosphatidylserine is required for phagocytosis of apoptotic cells by macrophages and fibroblasts. J Biol Chem 2001;276:1071-1077. (Pubitemid 32096530)
28. Bogdanski P, Pupek-Musialik D, Dytfeld J, Lacinski M, Jablecka A, Jakubowski H: Plasma homocysteine is a determinant of tissue necrosis factor-alpha in hypertensive patients. Biomed Pharmacother 2008;62:360-365. (Pubitemid 351899101)
29. Poddar R, Sivasubramanian N, DiBello PM, Robinson K, Jacobsen DW: Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells: implications for vascular disease. Circulation 2001;103:2717-2723. (Pubitemid 32538788)
30. Wang G, Siow YL, O K: Homocysteine stimulates nuclear factor kappaB activity and monocyte chemoattractant protein-expression in vascular smooth-muscle cells: a possible role for protein kinase C. Biochem J 2000;352:817-826.
31. Gori AM, Corsi AM, Fedi S, Gazzini A, Sofi F, Bartali B, Bandinelli S, Gensini GF, Abbate R, Ferrucci L: A proinflammatory state is associated with hyperhomocysteinemia in the elderly. Am J Clin Nutr 2005;82:335-341.
32. Lazzerini PE, Capecchi PL, Selvi E, Lorenzini S, Bisogno S, Galeazzi M, Laghi PF: Hyperhomocysteinemia, inflammation and autoimmunity. Autoimmun Rev 2007;6:503-509. (Pubitemid 47069976)
33. Wang G, Woo CW, Sung FL, Siow YL, O K: Increased monocyte adhesion to aortic endothelium in rats with hyperhomocysteinemia: role of chemokine and adhesion molecules. Arterioscler Thromb Vasc Biol 2002;22:1777-1783. (Pubitemid 35331053)
34. Zakai NA, Katz R, Jenny NS, Psaty BM, Reiner AP, Schwartz SM, Cushman M: Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: the Cardiovascular Health Study. J Thromb Haemost 2007;5:1128-1135. (Pubitemid 46902111)